Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Phase 1

Active, not recruiting

Conditions: Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Biological: Filgrastim
Drug: Fludarabine
Drug: Mycophenolate Mofetil
Drug: Sorafenib
Drug: Tacrolimus

First Posted Date: 2017-08-11

Last Posted Date: 2024-04-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 74

Registration Number: NCT03247088

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Recruiting

Conditions: B Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Lymphoblastic Leukemia
Philadelphia Chromosome Positive
Recurrent Adult Acute Lymphoblastic Leukemia
Minimal Residual Disease
Refractory Acute Lymphoblastic Leukemia
CD19 Positive

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration

First Posted Date: 2017-08-08

Last Posted Date: 2024-07-11

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 50

Registration Number: NCT03241940

Locations: 🇺🇸
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States

Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

Phase 1

Completed

Conditions: AL Amyloidosis

Interventions: Drug: Ixazomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2017-08-02

Last Posted Date: 2022-09-29

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 28

Registration Number: NCT03236792

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Phase 1

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia
Minimal Residual Disease
CD19 Positive
Philadelphia Chromosome Positive

Interventions: Biological: Chimeric Antigen Receptor T-Cell Therapy
Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Drug: NKTR-255

First Posted Date: 2017-07-31

Last Posted Date: 2024-02-28

Lead Sponsor: Crystal Mackall, MD

Target Recruit Count: 56

Registration Number: NCT03233854

Locations: 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States

Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy

Phase 1

Terminated

Conditions: DLBCL

Interventions: Drug: Entospletinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2017-07-21

Last Posted Date: 2020-09-02

Lead Sponsor: The Lymphoma Academic Research Organisation

Target Recruit Count: 25

Registration Number: NCT03225924

Locations: 🇧🇪
UCL Namur, Yvoir, Belgium
🇧🇪
Institut Jules Bordet, Bruxelles, Belgium
🇧🇪
Az Groeninge, Kortrijk, Belgium

and more 24 locations

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Phase 1

Recruiting

Conditions: AIDS-Related Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Drug: Ibrutinib
Other: Laboratory Biomarker Analysis
Biological: Pegfilgrastim
Other: Pharmacological Study
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2017-07-18

Last Posted Date: 2024-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT03220022

Locations: 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States

and more 18 locations

Autologous Stem Cell Transplant for Crohn's Disease

Phase 2

Recruiting

Conditions: Crohn Disease

Interventions: Procedure: Autologous stem cell transplant
Drug: Cyclophosphamide
Drug: Thymoglobulin
Drug: Methylprednisolone
Drug: Vedolizumab

First Posted Date: 2017-07-17

Last Posted Date: 2024-09-30

Lead Sponsor: Aaron Etra

Target Recruit Count: 50

Registration Number: NCT03219359

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.

Phase 1

Recruiting

Conditions: Lymphocytic Leukemia

Interventions: Drug: NeoVax
Drug: Cyclophosphamide
Drug: Pembrolizumab

First Posted Date: 2017-07-17

Last Posted Date: 2024-04-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 15

Registration Number: NCT03219450

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Squamous Cell Carcinoma
Adenosquamous Carcinoma
Advanced NSCLC
Adenocarcinomas
Metastatic Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer

Interventions: Procedure: Tumor-infiltrating Lymphocytes (TIL)
Drug: Nivolumab
Drug: Cyclophosphamide
Drug: Fludarabine
Other: Tumor-infiltrating Lymphocyte Therapy
Drug: Interleukin-2 (IL2)

First Posted Date: 2017-07-12

Last Posted Date: 2023-07-24

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 20

Registration Number: NCT03215810

Locations: 🇺🇸
University of Florida Health Cancer Center., Gainesville, Florida, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

Phase 3

Recruiting

Conditions: Mature B-cell Non-Hodgkin Lymphoma

Interventions: Drug: Rituximab window
Drug: Cyclophosphamide
Drug: Additional doses of Rituximab
Drug: Cytarabine
Drug: Dexamethasone
Drug: Etoposide
Drug: Doxorubicin hydrochloride
Drug: Ifosfamide
Drug: Vindesine Sulfate
Drug: Methotrexate
Drug: Prednisolone
Drug: Vincristine

First Posted Date: 2017-07-02

Last Posted Date: 2023-12-11

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 650

Registration Number: NCT03206671

Locations: 🇫🇮
Turku University Hospital, Paediatric and Adolescent Haematology and Oncology, Turku, Finland
🇨🇭
Universitäts-Kinderspital, Pädiatrische Onkologie, Zürich, Switzerland
🇨🇭
Kinderspital Pädiatrische Hämatologie/ Onkologie, Luzern, Switzerland

and more 89 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy